Ribavirin for Paramyxovirus Infections in Hematopoietic Stem-Cell Transplant and Lung Transplant Recipients: Evaluation of an Optimized Dosing Regimen | Synapse
March 12, 2026Open Access
Ribavirin for Paramyxovirus Infections in Hematopoietic Stem-Cell Transplant and Lung Transplant Recipients: Evaluation of an Optimized Dosing Regimen
Key Points
The aim is to evaluate if a fixed-dose ribavirin regimen is more effective than a conventional weight-based approach for transplant recipients.
Comparison of fixed-dose and weight-based ribavirin dosing regimens
Focus on hematopoietic stem-cell and lung transplant recipients
Assessment of ribavirin target concentration achievement
Fixed-dose regimen achieves target concentrations more effectively than the weight-based regimen
Improvement in efficacy suggests a potential shift in dosing strategies for ribavirin
Abstract
These findings suggest that the proposed fixed-dose regimen is more effective than the conventional weight-based regimen for achieving ribavirin target concentrations.